Your browser is no longer supported. Please, upgrade your browser.
Settings
AUPH Aurinia Pharmaceuticals Inc. daily Stock Chart
AUPH [NASD]
Aurinia Pharmaceuticals Inc.
Index- P/E- EPS (ttm)-0.69 Insider Own- Shs Outstand94.33M Perf Week94.46%
Market Cap1.46B Forward P/E- EPS next Y-0.55 Insider Trans- Shs Float65.10M Perf Month191.87%
Income- PEG- EPS next Q-0.15 Inst Own- Short Float14.63% Perf Quarter166.21%
Sales0.32M P/S4579.85 EPS this Y-54.50% Inst Trans- Short Ratio3.85 Perf Half Y148.63%
Book/sh1.31 P/B11.77 EPS next Y46.10% ROA- Target Price11.92 Perf Year145.86%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range3.52 - 17.48 Perf YTD126.39%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-11.67% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low338.64% ATR1.14
Employees39 Current Ratio- Sales Q/Q-38.70% Oper. Margin- RSI (14)92.97 Volatility11.57% 8.76%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume6.18 Prev Close15.00
ShortableYes LT Debt/Eq- EarningsNov 14 AMC Payout- Avg Volume2.47M Price15.44
Recom1.70 SMA20130.40% SMA50174.53% SMA200152.35% Volume14,114,639 Change2.93%
Mar-16-18Reiterated Cantor Fitzgerald Overweight $14 → $16
Feb-08-18Initiated RBC Capital Mkts Outperform $9
Oct-30-17Reiterated H.C. Wainwright Buy $10 → $12
May-18-17Reiterated H.C. Wainwright Buy $12 → $10
Apr-11-17Initiated Cantor Fitzgerald Overweight $14
Mar-22-17Reiterated FBR & Co. Outperform $9 → $11
Dec-30-16Reiterated H.C. Wainwright Buy $10 → $8
Aug-17-16Reiterated H.C. Wainwright Buy $7 → $10
Jun-30-16Initiated H.C. Wainwright Buy $7
May-08-15Initiated MLV & Co Buy $9
Dec-09-19 06:01AM  Aurinia Announces Public Offering of Common Shares Business Wire
Dec-07-19 08:35AM  The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling Benzinga
Dec-06-19 07:39AM  The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend Benzinga
05:00AM  A 60% Tumble for Sage Therapeutics, and Two More Numbers to Know Barrons.com
Dec-05-19 10:08AM  Biotech Stocks Are Making Wild Moves Amid a Deluge of Trial Data Barrons.com +78.78%
08:51AM  Aurinia's Lupus Candidate Succeeds in Pivotal Study, Stock Up Zacks
07:14AM  The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission Benzinga
Dec-04-19 04:59PM  Aurinia Pharmaceuticals surges more than 110%, after positive trial for lupus-related drug MarketWatch +5.14%
04:05PM  Aurinia Announces Positive AURORA Phase 3 Trial Results Demonstrating Voclosporin Superiority Over Standard of Care in Lupus Nephritis Business Wire
Dec-03-19 06:30AM  Aurinia to Present Preclinical Voclosporin Data at 2020 Keystone Symposia Conference Business Wire +5.28%
Dec-02-19 08:38AM  Aurinia Pharmaceuticals (AUPH) Catches Eye: Stock Jumps 9.8% Zacks
05:07AM  Aurinia Pharmaceuticals Inc.'s (TSE:AUP) Shift From Loss To Profit Simply Wall St.
Nov-14-19 05:15PM  Aurinia Pharmaceuticals (AUPH) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:02PM  Aurinia Reports Third Quarter 2019 Financial Results and Recent Operational Highlights Business Wire
Nov-13-19 04:05PM  Aurinia Announces Updates to the Board of Directors Business Wire +6.79%
Nov-09-19 03:55PM  Were Hedge Funds Right About Souring On Aurinia Pharmaceuticals Inc (AUPH)? Insider Monkey
Nov-07-19 10:30AM  Aurinia Pharmaceuticals (AUPH) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
10:02AM  Options Traders Expect Huge Moves in Aurinia (AUPH) Stock Zacks
06:30AM  Aurinia Completes Voclosporin Drug-Drug Interaction Study Demonstrating No Clinically Significant Interaction With Mycophenolate Mofetil Business Wire
Nov-06-19 04:05PM  Aurinia Pharmaceuticals to Release Third Quarter 2019 Financial Results on November 14, 2019 Business Wire
Oct-31-19 06:30AM  Aurinia Announces Initiation of Patient Dosing in Phase 2/3 AUDREY Clinical Trial for Dry Eye Syndrome Business Wire
Oct-17-19 10:11AM  Aurinia Pharmaceuticals (AUPH) Catches Eye: Stock Jumps 6.2% Zacks
Oct-16-19 06:30AM  Aurinia Reports Last Patient Study Visit in Aurora Phase 3 Lupus Nephritis Study and Provides Update on ATM Facility Business Wire +6.21%
Oct-15-19 06:15AM  Does The Aurinia Pharmaceuticals Inc. (TSE:AUP) Share Price Fall With The Market? Simply Wall St. +20.36%
Oct-07-19 08:34AM  3 Biotech Stocks That Could Triple in 2020 TipRanks
Sep-26-19 04:05PM  Aurinia Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference Business Wire
Sep-23-19 08:52AM  Options Traders Expect Huge Moves in Aurinia (AUPH) Stock Zacks
Sep-19-19 11:01AM  Introducing Aurinia Pharmaceuticals (TSE:AUP), The Stock That Zoomed 181% In The Last Three Years Simply Wall St.
Sep-13-19 05:11PM  Aurinia Establishes At-the-Market Facility Business Wire
Sep-06-19 06:05AM  Aurinia Pharmaceuticals to Present at the 21st Annual H.C. Wainwright Global Investment Conference Business Wire
Aug-22-19 11:53AM  Aurinia Pharmaceuticals Inc. (TSE:AUP): A Fundamentally Attractive Investment Simply Wall St.
Aug-10-19 06:00AM  An Example of How I Stalk a Trade TheStreet.com
Aug-06-19 06:05PM  Aurinia Pharmaceuticals (AUPH) Reports Q2 Loss, Lags Revenue Estimates Zacks
04:02PM  Aurinia Reports Second Quarter 2019 Financial Results and Operational Highlights Business Wire
Aug-01-19 10:33AM  Will Aurinia Pharmaceuticals (AUPH) Report Negative Q2 Earnings? What You Should Know Zacks
Jul-30-19 06:00AM  Aurinia- From Dry Eye to Lupus Nephritis MoneyShow
Jul-18-19 06:30AM  Aurinia Announces Further Strengthening of the Senior Management Team Business Wire
Jun-27-19 08:02AM  ILJIN Comments on Aurinia Pharmaceuticals Annual Meeting Business Wire
Jun-26-19 07:00PM  Aurinia Shareholders Elect all Eight Directors at 2019 Annual General Meeting Business Wire
Jun-21-19 07:59AM  ILJIN Chairman Issues Open Letter to Aurinia Shareholders Business Wire
06:30AM  Aurinia Reminds Shareholders to Vote the YELLOW Proxy Prior to June 24 Deadline Business Wire
Jun-20-19 08:00AM  As Deadline Approaches ILJIN SNT Reminds Aurinia Shareholders to Vote the GREEN Proxy for Nominees Committed to Correcting Governance Failures and to Realizing Aurinias Full Potential Business Wire
Jun-19-19 06:30AM  Leading Independent Proxy Advisors Recommend Aurinia Shareholders Vote the YELLOW Proxy Card FOR All of Aurinias Director Nominees Business Wire
Jun-12-19 08:00AM  ILJIN SNT Files Investor Presentation, Urging Aurinia Shareholders to Correct Governance Failures and Director Conflicts Business Wire
Jun-10-19 02:58PM  ILJIN SNT Sends Letter to Shareholders of Aurinia Highlighting Governance Failures and Director Conflicts and Responding to Misleading Information Business Wire
Jun-07-19 08:00AM  Aurinia Issues Letter to Shareholders Business Wire
Jun-04-19 04:05PM  Aurinia Pharmaceuticals to Present at Upcoming Investor Conferences Business Wire
Jun-03-19 03:09PM  Largest Shareholder of Aurinia Pharmaceuticals, ILJIN SNT, Files Proxy Circular and Issues Letter to Fellow Shareholders Business Wire
May-31-19 08:30AM  Aurinia Pharmaceuticals Announces Upcoming Annual General Meeting of Shareholders Business Wire
May-17-19 04:02PM  Aurinia Pharmaceuticals to Present at the RBC Capital Markets Global Healthcare Conference Business Wire
May-14-19 05:15PM  Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss Zacks
04:10PM  Aurinia: 1Q Earnings Snapshot Associated Press
04:02PM  Aurinia Reports First Quarter 2019 Financial Results and Recent Operational Highlights Business Wire
May-10-19 07:00AM  Aurinia Recognizes World Lupus Day and Lupus Awareness Month with Activities Focused on Raising Awareness for Lupus Nephritis Business Wire
May-02-19 10:33AM  Aurinia Pharmaceuticals (AUPH) May Report Negative Earnings: Know the Trend Ahead of Q1 Release Zacks
Apr-30-19 06:05AM  Aurinia Further Strengthens Its Board of Directors with the Appointment of Dr. Daniel Billen Business Wire
Apr-24-19 04:05PM  Aurinia Pharmaceuticals to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference Business Wire
Apr-22-19 02:41PM  Former MedImmune president Greenleaf tapped to lead Canadian biotech American City Business Journals
Apr-11-19 04:30PM  Aurinia Announces Appointment of Peter Greenleaf as Chief Executive Officer and Board Director and the Elevation of Dr. George M. Milne, Jr. to Chairman of the Board Business Wire
Apr-10-19 08:46AM  Implied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock Options Zacks
Mar-19-19 10:14PM  Aurinia Pharmaceuticals Inc (AUPH) Q4 2018 Earnings Conference Call Transcript Motley Fool
04:14PM  Aurinia: 4Q Earnings Snapshot Associated Press
04:02PM  Aurinia Reports Fourth Quarter and Full Year 2018 Financial Results and Operational Highlights Business Wire
02:30PM  Aurinia Pharmaceuticals Inc. to Host Earnings Call ACCESSWIRE
Mar-14-19 07:00AM  Aurinia Recognizes World Kidney Day and National Kidney Month with New Activities Focused on Raising Awareness for Kidney Disease Business Wire
Mar-12-19 10:30AM  Analysts Estimate Aurinia Pharmaceuticals (AUPH) to Report a Decline in Earnings: What to Look Out for Zacks
Mar-07-19 04:05PM  Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year 2018 Financial Results on March 19, 2019 Business Wire
Feb-27-19 11:39AM  After Patent News, Aurinia Pharmaceuticals Still Has More to Prove InvestorPlace
06:30AM  Aurinia Closes At-The-Market Facility Business Wire
Feb-26-19 01:28PM  Big Pharma faces the Senate in drug price hearings Yahoo Finance Video
Feb-25-19 04:16PM  Here's Why Aurinia Pharmaceuticals' Stock Jumped Today Motley Fool +16.32%
07:00AM  Aurinia Receives Notice of Allowance from the US Patent and Trademark Office for Claims Directed to Its Novel Voclosporin Dosing Protocol for Lupus Nephritis Business Wire
Feb-20-19 04:01PM  Aurinia to Present at the 8th Annual SVB Leerink Global Healthcare Conference New York City Business Wire
Jan-30-19 02:33PM  Is Aurinia Pharmaceuticals a Buy? Motley Fool
08:10AM  Factors of Influence in 2019, Key Indicators and Opportunity within Leidos, Nomad Foods, Huron Consulting Group, Casella Waste, The Medicines, and Aurinia Pharmaceuticals New Research Emphasizes Economic Growth GlobeNewswire
Jan-22-19 09:09AM  Aurinia's Dry Eye Syndrome Drug Produces Mixed Results In Mid-Stage Trial Benzinga -8.74%
07:00AM  Aurinia Announces Voclosporin Ophthalmic Solution Demonstrates Statistically Superior Efficacy Versus Restasis® in a Phase 2 Head-to-Head Study for the Treatment of Dry Eye Syndrome Business Wire
Jan-21-19 04:49PM  Aurinia to Hold Conference Call and Webcast to Discuss Results of Phase 2 Head-to-Head Study of Voclosporin Ophthalmic Solution versus Restasis® for the Treatment of Dry Eye Syndrome Business Wire
08:45AM  Do Options Traders Know Something About Aurinia Pharmaceuticals (AUPH) Stock We Don't? Zacks
Jan-16-19 08:20AM  My Rx for How to Buy Aurinia Pharmaceuticals on Its Breakout TheStreet.com
Dec-20-18 12:10PM  4 Pharma Stocks Getting a Boost on Thursday (12/20/18) ACCESSWIRE
Dec-19-18 08:00AM  Aurinia to Present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco Business Wire
Nov-30-18 05:18PM  Aurinia Establishes at-the-Market Facility Business Wire
Nov-27-18 08:00AM  Analysis: Positioning to Benefit within Abeona Therapeutics, Great Lakes Dredge & Dock, Imprimis Pharmaceuticals, Alliant Energy, Cytokinetics, and Aurinia Pharmaceuticals Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Nov-09-18 07:00AM  Aurinia to Participate in November Investor Conferences Business Wire
Nov-08-18 05:45PM  Aurinia Pharmaceuticals (AUPH) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:39PM  Aurinia: 3Q Earnings Snapshot Associated Press
04:02PM  Aurinia Reports Third Quarter Financial Results, Clinical Highlights and Corporate Development Business Wire
Oct-25-18 07:00AM  Aurinia Pharmaceuticals to Release Third Quarter Financial Results and General Business Updates on November 8, 2018 Business Wire +5.71%
Oct-16-18 08:55AM  New Research: Key Drivers of Growth for Haverty Furniture Companies, BLACKLINE INC, MagnaChip Semiconductor, Kinross Gold, Aurinia Pharmaceuticals, and NEXEO SOLUTIONS Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Oct-03-18 05:49PM  Here's What Pushed Aurinia Pharmaceuticals Inc. Up 16.8% in September Motley Fool
Sep-28-18 08:31AM  Aurinia Pharmaceuticals (AUPH) in Focus: Stock Moves 6.7% Higher Zacks
Sep-26-18 08:25AM  The Daily Biotech Pulse: Verastem's Chinese Duvelisib Licensing Deal, Aldeyra's Positive Dry Eye Disease Drug Trial Benzinga
Sep-25-18 04:01PM  Aurinia Completes Enrollment of AURORA, its Phase 3 Clinical Trial for the Treatment of Lupus Nephritis Business Wire
Sep-19-18 04:01PM  Aurinia to Participate in Upcoming Investor Conferences Business Wire
Aug-28-18 07:00AM  Aurinia Announces Participation at the 20th Annual Global Investment Conference in New York City September 4-6, 2018 Business Wire
Aug-17-18 07:35AM  Investor Expectations to Drive Momentum within Natural Resource Partners LP, Insmed, MagnaChip Semiconductor, Changyou, Pain Therapeutics, and Aurinia Pharmaceuticals Discovering Underlying Factors of Influence GlobeNewswire
Aug-09-18 05:35PM  Aurinia Pharmaceuticals (AUPH) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:31PM  Aurinia: 2Q Earnings Snapshot Associated Press
04:02PM  Aurinia Reports Second Quarter Financial Results and Operational Highlights Business Wire
Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of various diseases in the United States and China. The company is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.